表紙
市場調查報告書

生物可吸收支架的全球市場 - 成長,趨勢及預測(2017年∼2022年)

Bioabsorbable Stents Market - Growth, Trends, and Forecast (2019 - 2024)

出版商 Mordor Intelligence LLP 商品編碼 391471
出版日期 內容資訊 英文 118 Pages
商品交期: 2-3個工作天內
價格
生物可吸收支架的全球市場 - 成長,趨勢及預測(2017年∼2022年) Bioabsorbable Stents Market - Growth, Trends, and Forecast (2019 - 2024)
出版日期: 2019年02月01日內容資訊: 英文 118 Pages
簡介

據世界衛生組織聲稱,全球心血管疾病是導致死亡的頭號死因,2012年造成約1750萬人死亡,佔全球死亡人數的31%。其中,估計有740萬是因冠心病引起的,670萬是因中風引起的。超過75%的死亡來自中等收入國家和低收入國家,因其中出生率較高,因此人口成長率較高。因此,已經患有心血管疾病的龐大人群以及這一人口基數增加的趨勢是這個市場的主要推動因素。

本報告提供全球生物可吸收支架市場調查,整體市場趨勢,各產品、地區的詳細趨勢,市場成長的影響要素分析,競爭情形,主要企業簡介等,總括性彙整。

目錄

第1章 簡介

  • 調查成果
  • 市場定義
  • 規模的單位
  • 基本貨幣
  • 檢討與預測期間
  • 一般的調查的前提條件
  • 關於報告

第2章 調查方法

  • 簡介
  • 分析方法論
  • 計量預測模式
  • 調查的前提條件

第3章 摘要整理

第4章 主要影響要素

第5章 市場概要與產業趨勢

  • 目前市場方案
  • 波特的五力分析
    • 供應商談判力
    • 買主談判力
    • 競爭程度
    • 替代品的威脅
    • 新加入廠商的威脅

第6章 成長要素,阻礙因素,機會及課題分析(DROC)

  • 市場成長要素
    • 心臟血管疾病造成的死亡人數世界第一
    • 老年人的劇增,尤其是已開發國家的增加
    • 生活方式的變化使青年人口容易得到心臟病
    • 心血管疾病的風險高的肥胖人口的擴大基礎
    • 消除各代產品出現任何並發症的風險產品所有併發症的風險
  • 市場阻礙因素
    • 嚴格法規方案
    • 高的設備成本
  • 市場機會
    • 各心血管疾病死亡率最高中、低所得國
    • 生活方式變化的新興市場
  • 主要課題
    • 確實的成果的替代品
    • 擴張後的反沖等的高的併發症風險

第7章 市場區隔

  • 各產品類型
    • 聚合物為基礎的生物可吸收支架
    • 金屬為基礎的生物可吸收支架
  • 各應用領域
    • 冠狀動脈疾病
    • 週邊動脈疾病
    • 其他
  • 吸收比
    • 低速吸收比
    • 中間吸收比
    • 高速吸收比
  • 各終端用戶
    • 醫院
    • 心臟中心
    • 研究所

第8章 各地理市場 - 各地區市場佔有率及預測

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 西班牙和葡萄牙
    • 義大利
    • 斯堪地那維亞
    • 荷比盧三國
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 其他
  • 中東、非洲地區(MENA)
    • GCC
    • 南非
    • 其他
  • 中南美
    • 阿根廷
    • 巴西
    • 其他

第9章 競爭情形

  • M&A
  • 新產品的銷售
  • 協定,合作,聯盟

第10章 主要供應商

  • Abbott Laboratories
  • 京都醫學規劃株式會社
  • Reva Medical
  • Elixir Medical Corporation
  • Amaranth Medical
  • Terumo Corporation
  • Arterius Limited
  • Biotronik
  • Xenogenics Corporation
  • Meril Life Sciences

由於第11章分析師的投資機會的展望

第12章 市場未來展望

第13章 附錄

  • 簡稱
  • 參考文獻
  • 免責聲明

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: 55008

Market Overview

The global bioabsorbable stents market was valued at USD 112.14 million in 2018, and is estimated to be valued at USD 183.28 million in 2024, witnessing a CAGR of 8.53%. Factors that are driving the market include a high prevalence of cardiovascular diseases, steep increase in the aging population, and the expanding base of the obese population.

As per the report of the World Health Organization (WHO), it is seen that the number one cause of death across the world is cardiovascular disease. Furthermore, the WHO has estimated that in 2016, approximately 17.9 million people died due to cardiovascular diseases (CVDs) which represents 31% of the total global deaths, and 85% of these deaths were due to heart attack and stroke. As reported by the Australian Heart Foundation, cardiovascular disease (CVD) is a major cause of death in Australia, with 43,477 deaths being attributed to CVD in Australia in 2017. Cardiovascular disease kills one Australian every 12 minutes. Hence, this global rise in the prevalence of CVD is expected to fuel the market growth.

Scope of the Report

According to the report, the polymer-based or metal-based stents dissolve or get absorbed in the body, and are expected to overcome complications and risks associated with metallic stents.

Key Market Trends

Polymer-based Bioabsorbable Stents Sub-segment is Expected to hold its Highest Market Share in the Product Type Segment

In the product type segment of the market, polymer-based bioabsorbable stents are believed to have the largest market size and are expected to witness a CAGR of 8.95% in the forecast period.

Bioabsorbable stents (BAS)/polymer-based bioabsorbable stents are made of the materials that can completely dissolve or be absorbed in the body. These are used both in peripheral and coronary artery disease. Most of the bioabsorbable stents are made of polylactic acid that is a naturally dissolvable material. However, the polymer materials, such as polycarbonates, polyesters, corrodible metals, and bacterial-derived polymers are under investigation for developing the next-generation bioabsorbable stents. The risk of the in-stent restenosis using drug-eluting and metallic stents (DES) has raised the need for bioabsorbable stents. The BAS has a low rate of late-stent thrombosis (LST) and restenosis, which led to the acceptance of BAS for clinical purposes. The product Absorb GT1 Bioresorbable Vascular Scaffold System (BVS) from Abbott was the first absorbable stent for coronary artery disease that received FDA in 2016, and was commercially available in Europe from 2011. However, on September 14, 2017, Abbott announced the end of sales of the Absorb bioresorbable vascular scaffold, due to poor sales and safety concerns, which led to a strong negative impact on the market. However, owing to the increased significance of the same, this sub-segment is expected to register substantial growth in the coming future.

Europe Dominates the Market and is Expected to do the Same in the Forecast Period

Europe currently dominates the market for bioabsorbable stents and is expected to continue its stronghold for a few more years. This region is expected to increase its market share in the future, owing to the increased usage of bioabsorbable stents. There is a rise in the usage because the region has a large number of people suffering from cardiovascular diseases and there is a huge demand for technologically advanced treatment options for the same.

Competitive Landscape

The bioabsorbable stents market is highly competitive and consists of several major players. In terms of market share, few of the major players currently dominate the market. However, with technological advancements and product innovations, mid-size to smaller companies are increasing their market presence by introducing new products at affordable prices. Companies, like Boston Scientific Corporation, Arterius Limited, Elixir Medical Corporation, Kyoto Medical Planning Co. Ltd, and Terumo Corporation, hold the substantial share in the market.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Introduction to Market Drivers and Restraints
  • 4.3 Market Drivers
    • 4.3.1 High Prevalence of Cardiovascular Diseases Globally
    • 4.3.2 Steep Increase in Aging Population
    • 4.3.3 Expanding Base of Obese Population
  • 4.4 Market Restraints
    • 4.4.1 Stringent Regulatory Scenario
    • 4.4.2 High Device Cost
    • 4.4.3 Safety Issues Related to Bioabsorbable Stents
  • 4.5 Industry Attractiveness - Porter's Five Forces Analysis
    • 4.5.1 Threat of New Entrants
    • 4.5.2 Bargaining Power of Buyers/Consumers
    • 4.5.3 Bargaining Power of Suppliers
    • 4.5.4 Threat of Substitute Products
    • 4.5.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Product
    • 5.1.1 Polymer-based Bioabsorbable Stents
    • 5.1.2 Metal-based Bioabsorbable Stents
  • 5.2 By Application
    • 5.2.1 Coronary Artery Disease
    • 5.2.2 Peripheral Artery Disease
  • 5.3 By Absorption Rate
    • 5.3.1 Slow Absorption Rate
    • 5.3.2 Fast Absorption Rate
  • 5.4 By End User
    • 5.4.1 Hospitals
    • 5.4.2 Other End Users
  • 5.5 Geography
    • 5.5.1 North America
      • 5.5.1.1 United States
      • 5.5.1.2 Canada
      • 5.5.1.3 Mexico
    • 5.5.2 Europe
      • 5.5.2.1 Germany
      • 5.5.2.2 United Kingdom
      • 5.5.2.3 France
      • 5.5.2.4 Italy
      • 5.5.2.5 Spain
      • 5.5.2.6 Rest of Europe
    • 5.5.3 Asia-Pacific
      • 5.5.3.1 China
      • 5.5.3.2 Japan
      • 5.5.3.3 India
      • 5.5.3.4 Australia
      • 5.5.3.5 South Korea
      • 5.5.3.6 Rest of Asia-Pacific
    • 5.5.4 Middle East & Africa
      • 5.5.4.1 GCC
      • 5.5.4.2 South Africa
      • 5.5.4.3 Rest of Middle East & Africa
    • 5.5.5 South America
      • 5.5.5.1 Brazil
      • 5.5.5.2 Argentina
      • 5.5.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Boston Scientific Corporation
    • 6.1.2 Arterius Limited
    • 6.1.3 Elixir Medical Corporation
    • 6.1.4 Kyoto Medical Planning Co. Ltd
    • 6.1.5 Terumo Corporation
    • 6.1.6 Abbott Laboratories Inc.
    • 6.1.7 Amaranth Medical
    • 6.1.8 Biotronik
    • 6.1.9 Meril Life Sciences Pvt. Ltd
    • 6.1.10 Reva Medical

7 MARKET OPPORTUNITIES AND FUTURE TRENDS